NO750295L - - Google Patents
Info
- Publication number
- NO750295L NO750295L NO750295A NO750295A NO750295L NO 750295 L NO750295 L NO 750295L NO 750295 A NO750295 A NO 750295A NO 750295 A NO750295 A NO 750295A NO 750295 L NO750295 L NO 750295L
- Authority
- NO
- Norway
- Prior art keywords
- virus
- strain
- atcc
- influenza type
- influenza
- Prior art date
Links
- 235000013601 eggs Nutrition 0.000 claims description 51
- 241000700605 Viruses Species 0.000 claims description 48
- 206010022000 influenza Diseases 0.000 claims description 43
- 229960005486 vaccine Drugs 0.000 claims description 36
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 33
- 239000001888 Peptone Substances 0.000 claims description 19
- 108010080698 Peptones Proteins 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 235000019319 peptone Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000002238 attenuated effect Effects 0.000 claims description 10
- 239000003381 stabilizer Substances 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 5
- 230000006798 recombination Effects 0.000 claims description 5
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 50
- 210000002966 serum Anatomy 0.000 description 26
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 25
- 229960000458 allantoin Drugs 0.000 description 25
- 238000012546 transfer Methods 0.000 description 24
- 230000035931 haemagglutination Effects 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 235000013330 chicken meat Nutrition 0.000 description 10
- 239000002054 inoculum Substances 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- 239000011521 glass Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 241000282339 Mustela Species 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 229960003971 influenza vaccine Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 241000831652 Salinivibrio sharmensis Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010040102 Seroma Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960001226 live attenuated influenza Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43917674A | 1974-02-04 | 1974-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO750295L true NO750295L (fi) | 1975-09-01 |
Family
ID=23743623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO750295A NO750295L (fi) | 1974-02-04 | 1975-01-30 |
Country Status (21)
Country | Link |
---|---|
JP (1) | JPS50107122A (fi) |
AT (1) | AT338416B (fi) |
BE (1) | BE824970A (fi) |
CA (1) | CA1047922A (fi) |
CH (1) | CH596316A5 (fi) |
CS (1) | CS202545B2 (fi) |
DD (1) | DD116474A5 (fi) |
DE (1) | DE2504373A1 (fi) |
DK (1) | DK141926B (fi) |
ES (1) | ES434384A1 (fi) |
FI (1) | FI750260A (fi) |
FR (1) | FR2259616B1 (fi) |
GB (1) | GB1439742A (fi) |
HU (1) | HU170522B (fi) |
IE (1) | IE42043B1 (fi) |
IL (1) | IL46446A (fi) |
LU (1) | LU71784A1 (fi) |
NL (1) | NL7501028A (fi) |
NO (1) | NO750295L (fi) |
SE (1) | SE424503B (fi) |
ZA (1) | ZA75248B (fi) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2588918A (en) * | 1947-11-07 | 1952-03-11 | William T Graham | Mechanism for raising and lowering plow frames relative to the ground wheels |
JPS6042209B2 (ja) * | 1974-05-31 | 1985-09-20 | 北里研究所(社団法人) | インフルエンザウイルスの新鮮分離株を発育鶏卵へ短期間で順化させる方法 |
-
1975
- 1975-01-14 ZA ZA00750248A patent/ZA75248B/xx unknown
- 1975-01-16 DK DK9775AA patent/DK141926B/da not_active IP Right Cessation
- 1975-01-16 IL IL46446A patent/IL46446A/xx unknown
- 1975-01-20 SE SE7500549A patent/SE424503B/xx unknown
- 1975-01-23 CA CA218,508A patent/CA1047922A/en not_active Expired
- 1975-01-24 FR FR7502331A patent/FR2259616B1/fr not_active Expired
- 1975-01-27 IE IE160/75A patent/IE42043B1/en unknown
- 1975-01-29 NL NL7501028A patent/NL7501028A/xx not_active Application Discontinuation
- 1975-01-30 BE BE152864A patent/BE824970A/xx not_active IP Right Cessation
- 1975-01-30 NO NO750295A patent/NO750295L/no unknown
- 1975-01-31 FI FI750260A patent/FI750260A/fi not_active Application Discontinuation
- 1975-02-01 ES ES434384A patent/ES434384A1/es not_active Expired
- 1975-02-03 JP JP50014790A patent/JPS50107122A/ja active Pending
- 1975-02-03 DD DD183973A patent/DD116474A5/xx unknown
- 1975-02-03 AT AT76675A patent/AT338416B/de not_active IP Right Cessation
- 1975-02-03 CH CH124275A patent/CH596316A5/xx not_active IP Right Cessation
- 1975-02-03 GB GB453575A patent/GB1439742A/en not_active Expired
- 1975-02-03 CS CS75669A patent/CS202545B2/cs unknown
- 1975-02-03 DE DE19752504373 patent/DE2504373A1/de not_active Withdrawn
- 1975-02-03 LU LU71784A patent/LU71784A1/xx unknown
- 1975-02-03 HU HUTE805A patent/HU170522B/hu unknown
Also Published As
Publication number | Publication date |
---|---|
FR2259616A1 (fi) | 1975-08-29 |
IL46446A0 (en) | 1975-04-25 |
SE424503B (sv) | 1982-07-26 |
FR2259616B1 (fi) | 1980-01-04 |
DK141926C (fi) | 1981-01-19 |
ATA76675A (de) | 1976-12-15 |
DE2504373A1 (de) | 1975-08-07 |
DD116474A5 (fi) | 1975-11-20 |
DK141926B (da) | 1980-07-21 |
IL46446A (en) | 1978-01-31 |
JPS50107122A (fi) | 1975-08-23 |
SE7500549L (fi) | 1975-08-05 |
IE42043B1 (en) | 1980-05-21 |
DK9775A (fi) | 1975-09-29 |
IE42043L (en) | 1975-08-04 |
CS202545B2 (en) | 1981-01-30 |
CH596316A5 (fi) | 1978-03-15 |
AT338416B (de) | 1977-08-25 |
LU71784A1 (fi) | 1975-06-24 |
FI750260A (fi) | 1975-08-05 |
ES434384A1 (es) | 1976-12-01 |
CA1047922A (en) | 1979-02-06 |
ZA75248B (en) | 1976-01-28 |
AU7734675A (en) | 1976-07-15 |
HU170522B (fi) | 1977-06-28 |
BE824970A (fr) | 1975-07-30 |
NL7501028A (nl) | 1975-08-06 |
GB1439742A (en) | 1976-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Saito et al. | Characterization of a human H9N2 influenza virus isolated in Hong Kong | |
US6635246B1 (en) | Inactivated influenza virus vaccine for nasal or oral application | |
Ruben et al. | A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity | |
Kendal | Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? | |
PERKINS et al. | Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route | |
US4552758A (en) | Human use of avian-human reassortants as vaccines for influenza A virus | |
US4009258A (en) | Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same | |
US4338296A (en) | Influenza virus and process of producing a vaccine therefrom | |
Tamura et al. | Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine | |
US5162112A (en) | Influenza vaccine | |
Gorse et al. | Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically III adults | |
Mostow et al. | Studies on inactivated influenza vaccines: II. Effect of increasing dosage on antibody response and adverse reactions in man | |
Kilbourne et al. | Influenza vaccines: Summary of influenza workshop V | |
US4318903A (en) | Live influenza virus vaccine and the preparation thereof | |
WO1992000097A1 (en) | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza | |
US20130315951A1 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
US3953592A (en) | Live influenza virus vaccines and preparation thereof | |
US3961046A (en) | Mumps vaccine and preparation thereof | |
US3962423A (en) | Live influenza type B virus vaccines and preparation thereof | |
CN101450208A (zh) | 喷鼻免疫流感多价疫苗的制备及其方法 | |
Romanova et al. | Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice | |
NO750295L (fi) | ||
CA1152895A (en) | Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them | |
Morris et al. | Antigenic relationship of 1961–1963 A2 influenza viruses to prototype A2 1957 strain | |
Clements et al. | Comparison of the virologic and immunologic responses of volunteers to live avian-human influenza A H3N2 reassortant virus vaccines derived from two different avian influenza virus donors |